FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... December 18, 2025 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver... July 3, 2026 Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... November 11, 2024 Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 Load more HOT NEWS Biopsie: 5 lucruri pe care fiecare pacient trebuie să le cunoască Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... EMA Recommends Extension of Indications for Crizotinib
